141 results about "Cerebral edema" patented technology

The invention discloses a craniocerebral injury degree diagnosis auxiliary system based on a medical image, and relates to the technical field of medical treatment, a primary judgment module can accurately judge whether a patient has the risk of interstitial encephaledema or not by analyzing the accumulation degree of interstitial fluid in white matter and quantitatively calculating a penetration anomaly coefficient Syxs, the ability of early risk screening is provided, and the risk of interstitial encephaledema can be accurately judged. Potential problems can be recognized in time before disease deterioration, a clinician is prompted to intervene rapidly, and therefore the prognosis effect of a patient is remarkably improved. When the risk of interstitial encephaledema exists, the type diagnosis module further distinguishes lesion types (such as brain contusion or other injuries) by extracting related distinguishing features in a multi-modal feature set, calculates a locking coefficient Sdxs, and provides a scientific quantitative basis for diagnosis of lesion types based on specific features of the lesions. According to the accurate type diagnosis method, diagnosis errors can be reduced, and reliable support is provided for clinical decision making.

The invention relates to the technical field of biological medicines, in particular to a sulfonamide compound for treatment and an enantiomer thereof as well as a preparation method and application thereof, and has the beneficial effects that the provided sulfonamide compound and the enantiomer thereof have the characteristics of strong stability, longer action effect, better drug effect and the like; the compound is a better diuretic and new anti-encephaledema medicine.

The invention belongs to the technical field of nerve regulation and control engineering, and provides a cerebrospinal fluid rhythm-based Alzheimer's disease electrical stimulation system, which is characterized in that first frequency band range data and second frequency band range data in brain wave signals are coupled to obtain cerebrospinal fluid rhythm data; then, calculating the phase difference between the first frequency band range data and the cerebrospinal fluid rhythm data; finally, the stimulation frequency is dynamically controlled according to the phase difference, and the stimulation current is dynamically controlled according to the brain tissue water volume fraction. The problem that specific metabolism requirements of non-fast eye movement sleep and fast eye movement sleep cycles cannot be matched by adopting single-frequency-band stimulation is solved, dynamic changes of post-traumatic encephaledema and requirements and influences of cerebrospinal fluid rhythm on current control are considered, the real-time adaptive capacity to the dynamic changes of the post-traumatic encephaledema is improved, and the application prospect is wide. And the treatment effect of the Alzheimer's disease is ensured.

The invention belongs to the technical field of disease drugs, and particularly relates to application of an engineered attenuated coxsackie B3 virus vector (CVB3 (mu)) in preparation of drugs for treating traumatic craniocerebral injury. According to the application disclosed by the invention, after severe craniocerebral injury of a mouse, CVB3 (mu) can remodel a host immune system through single intraperitoneal injection treatment, so that the absorption speed of encephaledema on an affected side can be remarkably increased, and the effect of treating traumatic craniocerebral injury is achieved; in addition, the CVB3 (mu) has remarkable safety.

The invention discloses a TREM-1 inhibitory peptide nano-particle which is prepared by the following steps: by taking a dendritic polymer PAMAM as a carrier, coupling a TREM-1 inhibitory peptide with amino groups on the carrier by utilizing the characteristic of polyamino groups on the surface of the PAMAM, and coupling a brain-targeted peptide with the other part of amino groups on the carrier through MAL-PEG2000-NHS, so as to obtain the TREM-1 inhibitory peptide nano-particle. And modifying the residual amino groups on the carrier with PEG (Polyethylene Glycol) to obtain the nano-particles. The nanoparticles can relieve encephaledema, neuroinflammation injury and blood brain barrier damage caused by traumatic craniocerebral injury, improve cognitive impairment and long-term prognosis after trauma, and have a very high curative effect on clinical treatment of craniocerebral injury.

Provided are methods for treatment of pathological conditions causing hemolysis, cerebral edema, acute kidney injury and non-anaphylactic shock, including envenomation, trauma, cerebral malaria and mast-cell diseases using at least one PLA2 inhibitor, alone or in combination with other agents. The unexpected versatility of PLA2 inhibitors, their dosage forms and combinations make them candidates as essential medicines for the developing world.

The invention belongs to the field of biological materials, and particularly relates to a multifunctional DNA nanometer material, a preparation method and application of the multifunctional DNA nanometer material in treatment of traumatic brain injury secondary encephaledema. The multifunctional DNA nano material comprises a plurality of deoxyribozyme (DNAzyme) targeting C1q mRNA (messenger Ribonucleic Acid) and a repeating unit which is integrally connected with G-quadruplex / Hemin in series, wherein the G-quadruplex / Hemin is labeled by streptavidin SA and biotin and is used for scavenging free radicals. The DNAzyme for silencing the C1q gene of the mouse is designed on the basis of a bioinformatics method, and the C1q gene overexpressed in an inflammation model can be knocked down to an approximate normal level. The RCA technology mediated self-assembled nano material SA-B / H has excellent enzyme mimetic activity, can effectively remove free radicals such as H2O2 and O2 <.->, and has the potential of in-vivo oxidation resistance. In-vitro experiments prove that SA-B / H can effectively relieve high-level oxidative stress of cells caused by H2O2 stimulation.

The invention relates to an application of a sulfonamide compound or a pharmaceutical composition containing the sulfonamide compound in preparation of an anti-encephaledema drug. The sulfonamide compound can quickly reduce intracranial pressure, is used for treating encephaledema caused by various reasons and preventing cerebral hernia, is high in safety, has no serious adverse effects such as liver and kidney injury and the like, and is a novel anti-encephaledema medicine.

The invention provides a brain injury simulation human teaching model which comprises a simulation human body with a head, a body and four limbs. A craniocerebral simulation unit for simulating encephaledema, encephaloma, brain fracture, cerebral hernia and cerebrospinal fluid leakage is arranged in the head part; a urinary system simulation unit, a blood circulation system simulation unit and a respiratory system simulation unit are arranged in the body; control programs of response of the urinary system simulation unit, the blood circulation system simulation unit and the respiratory system simulation unit corresponding to different brain injuries are preset in the controller; an operator selects different brain injuries and nurses the brain injuries and complications of the urinary system simulation unit, the blood circulation system simulation unit and the respiratory system simulation unit. The brain injury can be nursed through the craniocerebral simulation unit, the complication of the brain injury can be nursed through the urinary system simulation unit, the blood circulation system simulation unit and the respiratory system simulation unit, and the brain injury nursing system is more consistent with the actual situation and is beneficial to teaching.

The invention discloses a polypeptide Tat-CIRP and application thereof, the amino acid sequence of the polypeptide Tat-CIRP is as shown in SEQ ID NO.3, Tat is a transmembrane structure sequence of 11 amino acids on a Tat protein, and is specifically as shown in SEQ ID NO.1; cIRP is 14 amino acid sequences on a CIRP protein with the highest affinity with GPR68, and is specifically shown as SEQ ID NO. 2. It is found through experimental research that nerve injury and encephaledema after subarachnoid hemorrhage can be remarkably improved through polypeptide Tat-CIRP administration so as to relieve early brain injury, white matter injury is relieved by promoting myelin sheath repair after subarachnoid hemorrhage, and a complete experimental basis is provided for clinical application of the polypeptide Tat-CIRP.

A method of treating or preventing adverse outcomes associated with tissue plasminogen activator (tPA) administration, cerebral edema-related side effects, cerebral edema associated with radiation therapy, or migraine headaches by administering an effective amount of a SUR1-TRPM4 channel inhibitor, such as glyburide, and optionally the co-administration of a second therapeutically active agent, to a subject in need thereof. Adverse outcomes associated with tPA include cerebral hemorrhage, cerebral edema, physical impairment or death. The administration of the SUR1-TRPM4 channel inhibitors occurs prior to the radiation therapy, during the radiation therapy, after the radiation therapy, or combinations thereof. The SUR1-TRPM4 channel inhibitor is administered prior to surgical excision of a brain tumor, CAR-T therapy, or administration of flutarabine. Alternatively, or in addition, the SUR1-TRPM4 channel inhibitor is administered prior the onset of the cerebral edema-related side effects.

This invention discloses a data processing method and system based on the changing trends of image features, relating to the field of cerebral infarction early warning technology. The data processing method includes: feature extraction: processing image data and modal data separately using feature analysis methods to obtain image features, image feature change data, modal data features, modal data feature change data, and the regions where the features are located. In this invention, image data provides intuitive information about brain structure and lesions, while modal data supplements key features such as hemodynamics, brain tissue electrical activity, and electrical impedance from different physiological dimensions. TCD data can monitor blood flow velocity and vascular resistance in real time, BI data is sensitive to changes in pathological states such as cerebral edema, and EEG data reflects subtle changes in neuronal electrical activity. Through feature extraction and analysis, the combination of multi-source heterogeneous data achieves the correction of image feature changing trends, thereby ensuring the accuracy of data processing.

The invention belongs to the technical field of medical treatment, and discloses application of dehydroequol to treatment of neonatal hypoxic ischemic encephalopathy. The dehydroequol is used for treating the neonatal hypoxic-ischemic encephalopathy, and it is proved that the dehydroequol can reduce the area of cerebral infarction induced by hypoxia and ischemia, relieve encephaledema and inhibit oxidative stress and copper death, and has a treatment effect on neonatal hypoxic-ischemic brain injury. Dehydroequol is a medicine for treating hypoxic ischemic encephalopathy of newborns and has a development prospect.

The invention relates to the technical field of medicine, in particular to application of an Acp5 inhibitor in cerebral edema after traumatic brain trauma, and the Acp5 inhibitor comprises a medicine with the ACP5 inhibitor as an active component and a prodrug form of the medicine. According to the invention, through an enzyme-substrate key activation mechanism, a drug is coupled by using an ACP5 specific substrate peptide, dual response release is realized in a lesion area, and the targeting property and the safety are remarkably improved. The prodrug is composed of a core inhibitor module, an ACP5 substrate peptide module and a pH response connection module, and can accurately inhibit ACP5 + macrophage infiltration and reduce encephaledema volume and neuroinflammation. The application can effectively treat acute and chronic encephaledema, reduce off-target effect and side effect, and provide a brand new treatment strategy for traumatic brain trauma.

The invention relates to the technical field of medical biology, in particular to application of coriaria lactone or a medicinal derivative thereof in preparation of AD (Alzheimer's disease) treatment drugs. The coriaria lactone shows unique structural activity and treatment specificity, the epoxyhexane ring structure of the coriaria lactone is a key active group and is enriched in an A beta sedimentary area through synaptic gaps, the ion disturbance range is limited in a lesion microenvironment (the radius is lt and 50 microns), and wide tissue damage caused by physical electrical stimulation is avoided. The micromolecule characteristic (LogP = 1.8) of the coriaria lactone endows the coriaria lactone with the ability of spontaneously penetrating the blood brain barrier, the onset time is shortened to the hour level from several months, and meanwhile, the risk of encephaledema is avoided. Therefore, the compound can be used for preparing the medicine for treating the Alzheimer's disease, meanwhile, a proper dosage is screened, and a foundation is laid for research on preparation of the medicine for treating the AD.

The invention provides application of an expression inhibitor of FOXO3a in preparation of a medicine for treating acute brain injury after subarachnoid hemorrhage. The research finds that FOXO3a is highly expressed in acute brain injury after subarachnoid hemorrhage, and further finds that knock-down of FOXO3a improves SAH mouse neurological function impairment and encephaledema and reduces lipid peroxidation injury. The results show that FOXO3a is a new target spot for treating acute brain injury after subarachnoid hemorrhage. It is indicated that the FOXO3a knockout reagent or / and the FOXO3a inhibitor is a potential novel medicine for treating acute brain injury after subarachnoid hemorrhage.

The present invention discloses a preparation method of rhein / berberine / glycyrrhizic acid hydrogel, which comprises the following steps: dispersing the rhein / berberine nanoparticle solution, glycyrrhizic acid and PBS solution uniformly, and standing to obtain the rhein / berberine / glycyrrhizic acid hydrogel; the concentration of glycyrrhizic acid in the hydrogel is 0.01-0.04 g / mL. The rhein / berberine / glycyrrhizic acid hydrogel prepared by the present invention has the characteristics of anti-inflammation, reducing edema, neuroprotection, etc., solves the limitation of poor curative effect of single-component drugs, realizes in-situ injection administration of three small-molecule drugs, and has synergistic effect, and is applied in drugs for treating inflammatory or edematous encephalopathy accompanied by traumatic brain injury, cerebral edema, Alzheimer's disease, Parkinson's disease, etc., and has obvious therapeutic effect.

The invention discloses a cerebral infarction risk early warning method and system based on an image feature change trend, and relates to the technical field of cerebral infarction early warning. The cerebral infarction risk early warning method comprises the steps of feature extraction, wherein image data and modal data are processed through a feature analysis method, and image features, image feature change data, modal data features, modal data feature change data and regions where the features are located are obtained; the image data provides visual information of a brain structure and a focus, the modal data supplements key features such as hemodynamics, brain tissue electrical activity and electrical impedance from different physiological dimensions, the TCD data can monitor blood flow velocity and vascular resistance in real time, and the BI data is sensitive to change of pathological states such as encephaledema. The EEG data reflects the subtle change of the electrical activity of neurons, and the image feature change trend is corrected through feature extraction and analysis and combination of multi-source heterogeneous data, so that the accuracy of cerebral infarction risk early warning is ensured.

The invention relates to the technical field of biological medicine, and particularly discloses a macrophage membrane coated plateau encephaledema drug carrier and a preparation method and application thereof, and the macrophage membrane coated plateau encephaledema drug carrier is composed of a nanoparticle core and a macrophage membrane shell layer wrapping the core; the nanoparticle core comprises an ROS-responsive carrier material and carbon monoxide release molecules MnCO entrapped in the ROS-responsive carrier material; the content of phosphatidylserine in the shell layer of the macrophage membrane is not less than 5 mol% of the total phospholipid of the membrane. According to the invention, a bionic delivery system of ROS response type MnCO nanoparticles coated with a macrophage membrane is constructed, phosphatidylserine on the surface of the membrane is utilized to actively activate a microglial cell Trem2 receptor, a positive feedback cycle of targeting phagocytosis-CO release-Trem2 up-regulation is formed, and at the same time, fatty acid oxidative metabolism reprogramming is promoted by means of degraded membrane lipid, so that the biomimetic delivery system is used for preparing the ROS response type MnCO nanoparticles. And multi-mechanism synergistic efficient brain-targeted therapy is realized.

To provide a compound which can be used for prevention, treatment and control of aquaporin-mediated conditions such as diseases of water imbalance, for example, cerebral edema, a pharmaceutical composition, and a method for producing the same.SOLUTION: There is provided a hydrate of 2 - {[3, 5-bis (trifluoromethyl) phenyl] carbamoyl} - 4-chlorophenyl dihydrogen phosphate represented by the following structure, which exhibits an XRPD pattern comprising at least five 2 θ (°) values selected from the group consisting of 8.8, 9.5, 11.1, 15.2, 15.5, 16.4, 20.2, 20.6, 23.6, 24.0, 24.9 and 27.2, wherein the XRPD is measured using an incident beam of CuK α radiation of 1.54059 Å.SELECTED DRAWING: None

A hypertonic saline (HTS) administration system comprising a sodium sensor for continuous monitoring of sodium concentration of a patient at a predetermined frequency, a infusion pump for delivery of HTS to the patient and a controller for adjusting the infusion rate of an infusion pump based on real-time measurement of sodium concentration of the patient. The sodium sensor comprises a sensor cable for placement through a catheter to position a distal sensor tip at a selected in vivo sensor site. A proximal end of the sensor cable seats within a connector fitting mounted on the catheter at a convenient and accessible subcutaneous position. The connector fitting couples the sensor cable to the controller which adjusts the infusion rate of the infusion pump.

The present invention relates to the field of medicine, and specifically to the use of taraxasterol or its salts in the preparation of drugs for preventing or treating traumatic brain injury. Animal experiments have confirmed that the taraxasterol of the present invention can improve the motor ability of the balance beam experiment in the neurological function score of mice with brain trauma, improve the neurological function scores including motor tests and sensory tests; reduce the permeability of the blood-brain barrier, reduce brain edema, improve the short-term lesion volume after traumatic brain injury, and inhibit microglial activation and immune cell infiltration. Cytological experiments have confirmed that taraxasterol can reduce microglia-mediated neuroinflammation, reduce the expression of inflammatory factors such as TNF-α, IL-6, and IL-1β, and reduce neuronal damage.

This invention relates to animal models and their applications, specifically to a method for constructing a spontaneous mouse cerebral edema model and its application. This invention utilizes PEN2... fl / + Mice and PEN2 fl / + Mice were mated to obtain PEN2. fl / fl Homozygous mice; then the obtained PEN2 fl / fl Mice and hGFAP Cre / + Mice were mated to obtain PEN2. fl / + hGFAP Cre / + Mice; the final PEN2 obtained fl / + hGFAP Cre / + Mice and PEN2 fl / fl Mice were mated to obtain PEN2. fl / fl hGFAP Cre / + The mouse model is a spontaneous mouse cerebral edema model. In this model, PEN2 protein levels are significantly downregulated, and the mouse exhibits a severe cerebral edema phenotype. This model can be used to establish a cerebral edema drug screening platform. It can also be used for research on cerebral edema-related diseases, such as the pathogenesis of cerebral edema caused by infection, glioma, and traumatic brain injury, as well as for the development of technologies and products for the diagnosis and treatment of related diseases.

The application discloses a kind of bioengineered apoptotic bodies based on apoptotic body membrane protein and liposome and preparation method and application thereof.The bioengineered apoptotic bodies are formed by the chimerization of apoptotic body membrane protein and liposome loaded with gastrodin and Cy5.The bioengineered apoptotic bodies simulating the natural apoptosis process of mesenchymal stem cells can promote the polarization of microglial cells to M2 type, release anti-inflammatory factors and neurotrophic factors, promote the proliferation of neurons, improve the antioxidant capacity of cells, improve the nervous motor function, relieve brain edema, and thus effectively treat traumatic brain injury.

The application provides a traditional Chinese medicine preparation for treating or improving cerebral hemorrhage and a preparation method thereof, and relates to the technical field of traditional Chinese medicine pharmacy. The traditional Chinese medicine preparation is composed of nacre, antelope horn powder, dragon's blood, Herba Schizonepetae, Prunella vulgaris, Stink-bug, Smilax riparia, bamboo juice, dried tangerine or orange peel, clubmoss, radix puerariae, Zizania aquatica and leaf of Chinese pear. The preparation has a significant therapeutic effect on cerebral hemorrhage, can obviously improve the neurological deficit of cerebral hemorrhage rats, reduce the water content of brain tissue to alleviate brain edema, simultaneously alleviate the inflammatory response in the body, thereby playing a neuroprotective effect on cerebral hemorrhage rats. In addition, the preparation can obviously improve the consciousness state of cerebral hemorrhage patients, alleviate the degree of neurological deficit, relieve the related TCM syndromes of the patients, simultaneously effectively improve the daily life ability of the patients, significantly improve the total effective rate of clinical treatment, and no obvious adverse reactions are observed in the treatment process, and the safety is good, thereby providing a safe and effective treatment scheme for the conservative treatment of cerebral hemorrhage.

The invention belongs to the technical field of biological medicines, and relates to a high-throughput screening method based on cell membrane nano-vesicles and application of a screened drug afloqualone in resisting encephaledema. Through a screening model, it is surprisingly found that the drug afloqualone AFQ on the market has the remarkable effect of inhibiting water inflow and encephaledema. The glibenclamide pharmaceutical composition shows a curative effect superior to that of glibenclamide in an animal model, can effectively reduce the volume of cerebral infarction, reduce the death rate in an acute stage and improve neurological impairment, and is known to have good clinical safety and good clinical application prospects. The invention provides a brand-new treatment strategy with a great clinical application prospect for solving the problem of lack of effective medicines for post-stroke encephaledema at present.

The invention provides a traditional Chinese medicine preparation for treating or improving cerebral hemorrhage and a preparation method thereof, and relates to the technical field of traditional Chinese medicine pharmacy, the traditional Chinese medicine preparation is composed of nacre mother of pearl, antelope horn powder, dragon's blood, motherwort fruit, selfheal, aspongopus, radix actinidiae chinensis, bamboo juice, pericarpium citri reticulatae, selaginella tamariscina, radix puerariae, zizania aquatica and folium eriobotryae. The traditional Chinese medicine composition can obviously improve neurological impairment of cerebral hemorrhage rats, reduce the water content of brain tissues to relieve encephaledema and reduce inflammatory response in vivo, thereby playing a role in protecting the nerves of the cerebral hemorrhage rats. Besides, the preparation can obviously improve the consciousness state of a cerebral hemorrhage patient, relieve the degree of neurological impairment, relieve related traditional Chinese medicine syndromes of the patient, effectively improve the daily living ability of the patient and obviously improve the total effective rate of clinical treatment, no obvious adverse reaction is observed in the treatment process, and the preparation is good in safety and free of toxic and side effects. And a safe and effective treatment scheme is provided for the conservative treatment of cerebral hemorrhage.

The present invention provides the use of α-asarone in the preparation of a drug for preventing or treating hemorrhagic stroke. The structure of α-asarone is shown in Formula I. It can significantly improve short-term neurological deficits and long-term learning and memory function in model rats, reduce cerebral edema, improve blood-brain barrier permeability, and prevent or alleviate brain tissue atrophy during the recovery period. It has a definite therapeutic effect on animal models of hemorrhagic stroke without significant toxic side effects, and is expected to become a promising drug for the prevention and treatment of hemorrhagic stroke. #imgabs0#

The application relates to an epilepsy monitoring and electric stimulation system and method, wherein the epilepsy monitoring and electric stimulation system comprises a multi-modal signal acquisition module, an electric stimulation module, a control module and a set of ring-shaped common electrodes distributed on a human head; in the multi-modal signal acquisition module, an electric impedance acquisition unit obtains impedance characteristics when the common electrodes are in a first acquisition state, and an electroencephalogram acquisition unit obtains electroencephalogram characteristics when the common electrodes are in a second acquisition state; the control module is used for evaluating an epilepsy pre-onset time, a lesion site and a brain edema degree based on the impedance characteristics, combining the two characteristics to evaluate an epilepsy grade, then setting electric stimulation parameters according to the brain edema degree and the epilepsy grade, selecting an electric stimulation electrode pair according to the lesion site, and controlling the electric stimulation module to apply electric stimulation with the parameters to the electrode pair before the epilepsy pre-onset time, and adjusting the parameters according to real-time signals in the stimulation. Through the application, the problems of low positioning accuracy and inability to intervene in time before epilepsy onset in the related art are solved.